Pharmaceuticals company Alivus Life Sciences announced Q1FY26 results Revenue from operations for Q1FY26 reached Rs 6,018 million, a growth of 2.2% YoY. EBITDA was at Rs 1,813 million, a growth of 9.9% YoY. EBITDA margins were at 30.1%, up 210 bps YoY. PAT for the quarter stood at Rs 1,215 million and PAT margins were at 20.2%. During Q1FY26, the company generated a strong free cash flow of Rs 1,000 million leading to Cash and Cash Equivalents (including short term investments) of Rs 6,604 million as of June 30, 2025. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said: "Our performance this quarter was primarily driven by strong growth in the Non-GPL business, which expanded by 14.5% YoY. Key regions including India (Ex-GPL), Europe, ROW, LATAM, and Japan were major contributors to this growth. We remain confident of achieving high single-digit revenue growth in FY26, with stronger momentum expected in the second half. Margins are projected to remain healthy in the 28–30% range. Our ongoing investments in capacity building and pipeline enrichment form the foundation of our future growth, and we believe these efforts, supported by an increasingly favourable market environment, will help unlock further value." Tushar Mistry, CFO, Alivus Life Sciences, said: "Q1FY26 witnessed robust revenues of Rs 602 crore, while consistently maintaining our gross margin at ~55% and EBITDA margin around ~30%, well within our guided range. This financial discipline, coupled with a healthy free cash flow of Rs 100 crore during the quarter, strengthens our debt-free balance sheet and positions us well to achieve the high single-digit growth we anticipate for the full year." Result PDF